Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations

INTRODUCTION: Tyrosine-kinase inhibitors (TKIs) represent the best treatment for advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 epidermal growth factor receptor mutation (EGFRm). This is an observational study investigating epidemiology, clinical features and tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Frega, Stefano, Lorenzi, Martina, Fassan, Matteo, Indraccolo, Stefano, Calabrese, Fiorella, Favaretto, Adolfo, Bonanno, Laura, Polo, Valentina, Zago, Giulia, Lunardi, Francesca, Attili, Ilaria, Pavan, Alberto, Rugge, Massimo, Guarneri, Valentina, Conte, PierFranco, Pasello, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464815/
https://www.ncbi.nlm.nih.gov/pubmed/28427238
http://dx.doi.org/10.18632/oncotarget.15945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464815/
https://www.ncbi.nlm.nih.gov/pubmed/28427238
http://dx.doi.org/10.18632/oncotarget.15945

Ejemplares similares